Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simcere Receives Chinese Approval To Manufacture, Sell Zanamivir
Zanamivir is marketed globally by GlaxoSmithKline (GSK) under the trade name, Relenza. Zanamivir is one of only two WHO approved drugs to which the new H1N1 strain of
Zanamivir is marketed globally by GlaxoSmithKline (GSK) under the trade name, Relenza. Zanamivir is one of only two WHO approved drugs to which the new H1N1 strain of
Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos
Under the terms of the agreement, Qiagen will have worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The new ResPlex assay detects
Proteome Sciences will assist Parexel early phase experts in helping biopharmaceutical companies advance biomarker discovery and qualification within clinical trials. This expanded capability allows Parexel to offer its
The investment program will be completed before the end of 2011. The centers will enforce sustainable development in the region and give a boost to Solvay’s presence in
Andrew Berlin, chairman and CEO of Berlin Packaging, said: “This exciting transaction unites two highly complementary businesses and will enable us to continue to unlock value for our
Group sales in the past financial year reached E1 billion. The pharma business, which now accounts for around three quarters of Group sales, again ensured a slight growth
Additionally, he will also work directly with Nutra Pharma licensees to coordinate ongoing marketing and outreach initiatives for the company’s drug pipeline, including its recently launched pain relievers,
The multinational study is investigating the safety and efficacy of Pari’s L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to Pari’s drug-device combination
The company claims that NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent), with extended half-life and increased biologic activity. The pre-clinical results showed a positive pharmacokinetic profile which